AIVITA Biomedical CEO Dr. Hans Keirstead Wins Innovator of the Year Award
IRVINE, Calif. – Sep. 13, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today…
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote Address at United Nations ‘AI for Good’ Meeting
IRVINE, Calif. – Sep. 13, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today…
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate
Personal vaccine made at point-of-care generated enhanced T-cell responses in 96.8% of evaluable subjects within 28 days Immediate and…
AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
IRVINE, Calif. – Nov. 16, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
IRVINE, Calif. – Nov. 8, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study
IRVINE, Calif. – Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
IRVINE, Calif. – Sept. 13, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative cell therapies,…